Agilent Technologies stock gains on digital pathology launch and strong Q3 figures
Article excerpt
Highlighted: the sentence this signal was extracted from
Agilent Technologies Inc (ISIN US00846U1016) stock is quoted at 149.98 USD as of September 4, 2026, only 1.1% above an intrinsic value estimate of 148.35 USD, according to data compiled by GuruFocus. On the same day, Agilent announced the U.S. launch of its Agilent S540MD Slide Scanner System following FDA approval, adding a new digital pathology solution to its diagnostics portfolio as highlighted in the news feed at StockTitan. For investors, the combination of a nearly fair valuation and fresh product momentum sets the tone for Agilent Technologies stock today. On September 4, 2026, Agilent Technologies expanded its digital pathology offering in the U.S. with the launch of the Agilent S540MD Slide Scanner System after receiving FDA clearance, according to the company press summary carried in the StockTitan news stream. The scanner is designed for high volume pathology laboratories and can process up to 540 slides, with continuous loading and compatibility with standard racks as described by GuruFocus. That capacity matters because large hospital and reference labs increasingly seek automated workflows that digitize glass slides and integrate into clinical information systems. The S540MD platform uses automated scanning and advanced tissue detection technologies to accelerate slide digitization and support comprehensive digital pathology workflows, again per the...
Keep reading with a free account
The rest of this article, and every signal for Agilent, is in your free account.
